VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has executed a non-binding Term Sheet for the sale of its wholly owned subsidiary, the Invictus BioPharma Pty Ltd Group to Invictus BioPharma Holdings Ltd.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly-owned subsidiary, Invictus Ops Pty Ltd, has received Human Research Ethics Committee (HREC) approval from a Lead Ethics Committee Site, Bellberry Ltd, for a Phase II clinical study on Non-Alcoholic Fatty Liver Disease.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that the Hong Kong Patent Office has granted a patent for the Transmucosal Delivery of Tocotrienols to its wholly-owned subsidiary, Invictus Biotechnology Pty Ltd.
Nanollose Limited (ASX:NC6) (FRA:N0L) is pleased to provide shareholders and investors with an overview of activities for the period ending 31 December 2021.
Invictus Ops Pty Ltd, a wholly owned subsidiary of NSX-listed VGI Health Technology Limited (NSX:VTL), is pleased to announce that it has contracted Resonance Health Ltd (ASX:RHT) to provide liver-fat quantification services for its clinical study on a potential new treatment for Non-Alcoholic Steatohepatitis.
Invictus Nutraceuticals, Inc. (Florida, USA), a wholly owned subsidiary of VGI Health Technology Limited (NSX:VTL), is pleased to announce that both NE1-Elite(R) and NE1-Heart(R) are now available for sale on Amazon in the United States.
The Directors of VGI Health Technology Limited (NSX:VTL) are pleased to provide the following update for the quarter ending 31 December 2021.
